Search
Inclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalBy binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnCefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigational[L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.
Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigational[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position
Bismuth subcitrate potassium
go.drugbank.com/drugs/DB09275ApprovedInvestigationalA bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
Tenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigationalTenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...
Gadopentetic acid
go.drugbank.com/drugs/DB00789ApprovedInvestigationalA complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
DDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia